Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 20, 2022

View Archived Issues

Oncostatin M blockade ameliorates severe asthma

Targeting DICAM impedes migration of disease-inducing leukocytes into the CNS in multiple sclerosis

Nanodecoys scavenge RANKL and TNF-alpha for osteoporosis treatment

Kallyope presents new AMPK activators

Jiangsu Hengrui Medicine and Shanghai Hengrui Pharmaceutical patent new ATR kinase inhibitors

Sun Pharmaceutical Industries divulges GIPR and GLP-1 receptor dual agonists

Medshine Discovery synthesizes new JAK3 inhibitors

Red Bull GmbH presents dopamine reuptake inhibitors

DNA-PK activates survival kinase AKT in response to DNA damage

Targeting specific behavioral immune traits of inflammation

BATF promotes lung tissue protection during acute respiratory virus infection

Targeting PARP could fight cancer-associated virus

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...